107 SPRING STREET, SEATTLE, WA
Annual Report to Security Holders
News
Atossa Therapeutics Enters $50 Million At the Market Offering Agreement
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
Atossa Therapeutics Approves 15:1 Reverse Stock Split Effective February 2, 2026
Atossa Therapeutics Estimates $40 Million Cash as of December 31, 2025
Receives FDA “Study May Proceed” Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Delisting Amendment